Osteoporosis is a progressive skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to increased bone fragility and susceptibility to fractures. Osteoporosis treatment includes drug therapies aimed at inhibiting bone resorption, stimulating bone formation, or a combination of both. The global osteoporosis treatment market is estimated to be valued at US$ 14.01 billion in 2023 and is expected to exhibit a CAGR of 3.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing prevalence of osteoporosis is expected to drive the growth of the osteoporosis treatment market during the forecast period. According to the International Osteoporosis Foundation, osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds. It is estimated that 1 in 3 women and 1 in 5 men over the age of 50 worldwide will experience osteoporotic fractures, owing to the rising prevalence of osteoporosis. This rising prevalence has increased the patient pool opting for osteoporosis treatment using drugs and therapies, thereby propelling the market growth.
Segment Analysis
The global osteoporosis treatment market is dominated by the drug segment, which accounted for over 80% market share in 2024. Among drugs, bisphosphonates dominates the market owing to its effectiveness in reducing fractures. Bisphosphonates inhibits osteoclastic bone resorption and reduces the risk of vertebral and hip fractures significantly. The non-bisphosphonate drugs segment, which includes estrogen inhibitors, parathyroid hormone therapy, and monoclonal antibodies, is expected to grow at a higher CAGR during the forecast period.
Key Takeaways
The global osteoporosis treatment market is expected to witness high growth over the forecast period of 2023 to 2030.
Regional analysis- North America currently dominates the global market owing to the rising incidences of osteoporosis and availability of advanced treatment options in the region. However, Asia Pacific is expected to grow at the highest CAGR during the forecast period due to growing geriatric population, rise in osteoporosis cases, and increasing healthcare expenditure.
Key players operating in the osteoporosis treatment market are Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Amgen Inc., Dr. Reddy’s Laboratories Ltd., Viatris Inc., Ligand Pharmaceuticals Incorporated, Eli Lilly and Company, Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co., Inc., GSK plc., and Pfizer Inc.
No comments:
Post a Comment